Abbvie (ABBV) Stock
Large pharmaceutical company with strong cash flow and dividend. Here's the price, business snapshot, and what's worth knowing about Abbvie in October 2026.
AbbVie Inc (ABBV) is a large-cap biopharmaceutical company known for established prescription medicines and an expanding pipeline. Historically driven by a few high-revenue products, AbbVie has sought to diversify through R&D, new product launches and acquisitions. The company generates significant free cash flow and is a regular dividend payer, which may attract income-focused investors. Key considerations for potential investors include patent and competition risks (including biosimilars), the outcome of clinical trials, regulatory approvals and pricing pressure in major markets. Market-cap scale and a broad geographic footprint can offer resilience, but revenues can be volatile around patent cliffs and product lifecycle events. This summary is for general educational purposes only and is not personal investment advice; investors should assess their own risk tolerance, time horizon and seek independent advice before acting. Past performance is not a guide to future results.
Why It’s Moving
AbbVie Pipeline Momentum Accelerates with Dual FDA Breakthroughs and Positive Phase III Data
- The FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A) for treating colorectal cancer and non-small cell lung cancer, marking the first such tags for this investigational antibody-drug conjugate.
- Phase III trial data showed that combining epcoritamab with standard R-CHOP therapy cut the risk of disease progression or death by 51% in patients with newly diagnosed diffuse large B-cell lymphoma compared to R-CHOP alone.
- Cantor Fitzgerald recently lifted price targets on AbbVie alongside other pharma giants, citing mixed growth outlooks but acknowledging the strength of the company's expanding drug portfolio.
AbbVie Pipeline Momentum Accelerates with Dual FDA Breakthroughs and Positive Phase III Data
- The FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A) for treating colorectal cancer and non-small cell lung cancer, marking the first such tags for this investigational antibody-drug conjugate.
- Phase III trial data showed that combining epcoritamab with standard R-CHOP therapy cut the risk of disease progression or death by 51% in patients with newly diagnosed diffuse large B-cell lymphoma compared to R-CHOP alone.
- Cantor Fitzgerald recently lifted price targets on AbbVie alongside other pharma giants, citing mixed growth outlooks but acknowledging the strength of the company's expanding drug portfolio.
Sixth Month Growth Performance
When is the next earnings date for AbbVie (ABBV)?
AbbVie Inc. is scheduled to release its next earnings report on October 30, 2026, before the market opens. This upcoming announcement will cover the company's financial results for the third quarter of fiscal year 2026. The confirmed date aligns with AbbVie’s historical reporting pattern, which typically occurs approximately three months after the previous quarterly release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AbbVie's stock, expecting it to rise towards the target price of $239.
Financial Health
AbbVie is performing well with strong revenues, profits, and cash flow, indicating good financial stability.
Dividend
AbbVie's average dividend yield of 2.49% offers a steady return for income-focused investors. If you invested $1000 you would be paid $24.90 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Large-cap pharma value
Generates strong cash flows and has a track record of dividends, which may suit income-oriented allocations — though yields and share performance can fluctuate.
Pipeline and innovation
New drug approvals and successful trials can drive growth, but R&D outcomes are uncertain and clinical setbacks are possible.
Global market exposure
A broad geographic footprint diversifies revenue sources, while differing regulations and pricing environments create both opportunity and risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
